Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?

Journal Article (Journal Article)

Next generation sequencing (NGS) coupled with sophisticated bioinformatics tools yields an unprecedented amount of information regarding tumor genetics, with the potential to reveal insights into tumor behavior. NGS and other multiplex genomic assays are rapidly spilling from the laboratory into the clinic through numerous commercial and academic entities. This raises the important question as to whether we are ready to use these data in clinical decision-making. While genetic lesions are clearly targeted by a new generation of biological cancer therapies, and certain regulatory approvals are actually coupled to single gene assays, we still do not know if the vast information on other genomic alterations is worth the added cost, or even worse, the inappropriate and unproven assignment of patients to treatment with an unapproved drug carrying potentially serious side effects. On the other hand, the trend toward a precision medicine pathway is clearly accelerating, and clinical trials validating pathway-driven personalized cancer therapeutics will be necessary in both the community and academic settings. Lower cost and wider availability of NGS now raises a debate over the merit of routine tumor genome-wide analysis.

Full Text

Duke Authors

Cited Authors

  • Tripathy, D; Harnden, K; Blackwell, K; Robson, M

Published Date

  • August 12, 2014

Published In

Volume / Issue

  • 12 /

Start / End Page

  • 140 -

PubMed ID

  • 25286031

Pubmed Central ID

  • PMC4244054

Electronic International Standard Serial Number (EISSN)

  • 1741-7015

Digital Object Identifier (DOI)

  • 10.1186/s12916-014-0140-3


  • eng

Conference Location

  • England